Dyne Therapeutics
Clinical trials sponsored by Dyne Therapeutics, explained in plain language.
A clinical-stage biotech developing muscle-targeted therapies for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug DYNE-101 aims to ease muscle symptoms in DM1
Disease control Recruiting nowThis Phase 3 trial tests whether DYNE-101 can improve muscle function and daily life in 150 adults with myotonic dystrophy type 1 (DM1). Participants receive either the drug or a placebo by IV every few weeks for 48 weeks. The study measures how quickly people can stand from a ch…
Phase 3 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug could help boys with duchenne walk and move longer
Disease control Recruiting nowThis study tests a new medicine called DYNE-251 in boys aged 4 to 18 with Duchenne muscular dystrophy (DMD) who can still walk. The goal is to see if it helps them move better and slows muscle damage. Participants will receive either the drug or a placebo every 4 weeks for about …
Phase 3 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug DYNE-101 aims to ease muscle stiffness in rare disease
Disease control Recruiting nowThis study tests a new medicine, DYNE-101, in 116 adults with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The main goals are to check if the drug is safe and if it can reduce muscle stiffness and improve muscle function. Participants re…
Phase 1/2 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC